Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for.
Item 1.03. Bankruptcy or Receivership. On October 30, 2023, after considering all strategic alternatives, Gelesis Holdings, Inc. , together with its U. S. subsidiaries,.
PureTech Health plc – Half-Year Report streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The anti-obesity drugs market size is forecast to increase by USD 13,693.43 million from 2022 to 2027, at a CAGR of 12.5%, according to the.